| Levosimendan for low cardiac output: a pediatric experience. | |
| | |
MedLine Citation:
|
PMID: 16672640 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
This was a retrospective observational study in a pediatric intensive care unit, in which 19 patients received levosimendan. There were no adverse events attributable to levosimendan and no instances where the clinical condition worsened after administration. Arterial lactate levels decreased significantly following levosimendan administration during cardiopulmonary bypass for anticipated low cardiac output. In those with established low cardiac output, trends toward improved hemodynamics were seen, with heart rate reduction, an increase in mean blood pressure, a reduction in arterial lactate, and reduced conventional inotrope use. Levosimendan was safely used in a small number of pediatric patients with established low cardiac output state who demonstrated improved hemodynamics and tissue perfusion, with a tendency to reduced conventional inotrope usage, and this warrants its evaluation as an inotrope in the pediatric population. |
| | |
Authors:
|
Jonathan R Egan; Andrew J B Clarke; Stephen Williams; Andrew D Cole; Julian Ayer; Stephen Jacobe; Richard B Chard; David S Winlaw |
Publication Detail:
|
Type: Journal Article |
Journal Detail:
|
Title: Journal of intensive care medicine Volume: 21 ISSN: 0885-0666 ISO Abbreviation: J Intensive Care Med Publication Date: 2006 May-Jun |
Date Detail:
|
Created Date: 2006-05-04 Completed Date: 2006-08-18 Revised Date: 2007-11-15 |
Medline Journal Info:
|
Nlm Unique ID: 8610344 Medline TA: J Intensive Care Med Country: United States |
Other Details:
|
Languages: eng Pagination: 183-7 Citation Subset: IM |
Affiliation:
|
Pediatric Intensive Care Unit, Children's Hospital at Westmead, Sydney, Australia. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adolescent Cardiac Output, Low / drug therapy*, etiology Cardiotonic Agents / administration & dosage, pharmacology, therapeutic use* Child Child, Preschool Drug Toxicity Heart Defects, Congenital / complications, drug therapy* Hemodynamics / drug effects Humans Hydrazones / administration & dosage, pharmacology, therapeutic use* Infant Infant, Newborn Infusions, Intravenous Pyridazines / administration & dosage, pharmacology, therapeutic use* Retrospective Studies |
| Chemical | |
Reg. No./Substance:
|
0/Cardiotonic Agents; 0/Hydrazones; 0/Pyridazines; 131741-08-7/simendan |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: The changing epidemiology of mechanical ventilation: a population-based study.
Next Document: The three-substituted indolinone cyclin-dependent kinase 2 inhibitor 3-[1-(3H-imidazol-4-yl)-meth-(Z...